Get the Stockscreener App
0.069
3.45%
0.0023
Pre-market:
.07
0.001
+1.45%
Onconetix Inc stock is traded at $0.069, with a volume of 3.26M.
It is up +3.45% in the last 24 hours and down -42.40% over the past month.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
See More
Previous Close:
$0.0667
Open:
$0.065
24h Volume:
3.26M
Relative Volume:
0.46
Market Cap:
$865.44K
Revenue:
-
Net Income/Loss:
$-53.12M
P/E Ratio:
-0.000634
EPS:
-108.8
Net Cash Flow:
$-15.86M
1W Performance:
+15.97%
1M Performance:
-42.40%
6M Performance:
-98.28%
1Y Performance:
-98.59%
1-Day Range:
$0.0617
$0.07
1-Week Range:
$0.052
$0.07
52-Week Range:
$0.0502
$21.40
Onconetix Inc Stock (ONCO) Company Profile
Name
Onconetix Inc
Sector
Industry
Phone
513-620-4101
Address
201 E. FIFTH STREET, CINCINNATI
Compare ONCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCO
Onconetix Inc
|
0.069 | 865.44K | 0 | -53.12M | -15.86M | -108.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.47 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.76 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.51 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.61 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.16 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Onconetix Inc Stock (ONCO) Latest News
Take off with Onconetix Inc (ONCO): Get ready for trading - Sete News
ONCO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Form 424B3Prospectus [Rule 424(b)(3)] - ADVFN
Form 8-KCurrent report - ADVFN
Onconetix faces third delisting threat since 2022 IPOCincinnati Business Courier - The Business Journals
Onconetix faces Nasdaq delisting over low share price By Investing.com - Investing.com India
Onconetix faces Nasdaq delisting over low share price - Investing.com
ONCO stock plunges to 52-week low, touches $0.06 - Investing.com Australia
ONCO stock plunges to 52-week low, touches $0.06 By Investing.com - Investing.com South Africa
Cincinnati's Onconetix pursuing merger deal with drug development firm - The Business Journals
Onconetix Sets Stage For Potential Business Combination With Ocuvex Therapeutics - MarketScreener
Onconetix eyes Ocuvex in potential merger to expand portfolio By Investing.com - Investing.com India
Onconetix, Ocuvex Therapeutics Sign Letter of Intent for Potential Merger; Shares Up Pre-Bell - marketscreener.com
Onconetix Inks Letter Of Intent For Potential Business Combination With Ocuvex - Nasdaq
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc. - The Manila Times
Max Alderman, Partner at FE International, Recognized as a NACVA 2024 30 Under Thirty Honoree - The Manila Times
Onconetix eyes Ocuvex in potential merger to expand portfolio - Investing.com
Target Corp (TGT) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Major Pipeline Expansion: Onconetix to Acquire FDA-Approved Eye Drug in Ocuvex Deal - Stock Titan
Another top executive departs Cincinnati public firm - WKRC
Onconetix executive chairman resigns in latest leadership exit; interim CFO named new top leader - The Business Journals
Onconetix Names Interim CFO Karina Fedasz as Interim CEO - MarketWatch
Onconetix Appoints Karina Fedasz as Interim CEO - TipRanks
Onconetix Delays Yearly Report Filing - TipRanks
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
Onconetix claims validation of prostate cancer test Proclarix in Danish cohort - Yahoo Finance
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort - GlobeNewswire
Onconetix reveals Proclarix’s clinical performance at EAU congress - Investing.com India
Onconetix Announces Successful Clinical Validation Of Proclarix For Prostate Cancer In Danish Cohort - Nasdaq
Onconetix reveals Proclarix’s clinical performance at EAU congress By Investing.com - Investing.com South Africa
Onconetix Inc. Presents Promising Clinical Data for Proclarix® at 2025 EAU Congress - Nasdaq
Onconetix Inc (NASDAQ: ONCO): Blank Check On Growth? - Stocks Register
Onconetix Announces New Clinical Data for its Innovative - GlobeNewswire
Onconetix to Present Proclarix at EAU Congress 2025 - TipRanks
Onconetix, Inc. to Present Proclarix Study Results at 2025 EAU Congress in Madrid - Nasdaq
Groundbreaking 800-Patient Study Shows How Onconetix's Proclarix Test Prevents Unnecessary Prostate Biopsies - StockTitan
ONCO stock plunges to 52-week low, touches $0.12 By Investing.com - Investing.com Australia
ONCO stock plunges to 52-week low, touches $0.12 - Investing.com India
Onconetix taps industry veteran as executive chairman amid CEO resignation - The Business Journals
Onconetix names new executive chairman, appoints board member By Investing.com - Investing.com Australia
Onconetix names new executive chairman, appoints board member - Investing.com India
Onconetix Announces Leadership Changes and New Appointments - TipRanks
Onconetix Says Ralph Schiess Resigns As Interim CEO And Chief Science Officer -February 28, 2025 at 05:35 pm EST - Marketscreener.com
Onconetix secures new financing, appoints auditor, sees executive exit By Investing.com - Investing.com South Africa
Onconetix secures new financing, appoints auditor, sees executive exit - Investing.com
Onconetix Announces Promissory Note Agreement with Keystone - TipRanks
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - MSN
Investing in Onconetix Inc (ONCO) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Onconetix Inc (ONCO) Stock: A Year of Decreases and Increases - The InvestChronicle
Daily Market Movement: Onconetix Inc (ONCO) Sees a 11.91 Increase, Closing at 0.61 - The Dwinnex
Onconetix files to sell 50M shares of common stock for holders - MSN
Onconetix Inc Stock (ONCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.04%
2.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):